log inhelp

 | 

  • If you are citizen of an European Union member nation, you may not use this service unless you are at least 16 years old.

  • You already know Dokkio is an AI-powered assistant to organize & manage your digital files & messages. Very soon, Dokkio will support Outlook as well as One Drive. Check it out today!

View
 

Referenties Polycysteus Ovarium Syndroom en depressie

Page history last edited by Nienke Aben 9 years, 12 months ago

Referenties

  1. Hooff M.H.A. van. Patiëntenvoorlichting PCOS: PolyCysteus Ovarium Syndroom. Nederlandse Vereniging voor Obstetrie en Gyneacologie. Utrecht; 2005.
  2. Niet J.E. de., Koning C.M. de, Pastoor H. et al. Psychological well-being and sexarche in women with polycystic ovary syndrome. Hum Reprod. 2010; 25(6): 1497-503.
  3. Norman R.J., Dewailly D., Legro R.S., Hickey, T.E. Polycystic ovary syndrome. The Lancet. 2007; 370(9588): 685-97.
  4. Sirmans S.M., Pate K.A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. J Clin Epidemiol. 2013; 6: 1-13.
  5. Heineman M.J., Evers J.L.H., Massuger L.F.A.G., Steegers E.A.P. Obstetrie en gynaecologie: de voortplanting van de mens. Maarssen: Elsevier Gezondheidszorg; 2007. 603-05.
  6. Fauser B.C., Tarlatzis B.C., Rebar R.W., et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Fertil Steril. 2012; 97(1): 28-38 e25.
  7. The Rotterdam ESHRE/ASRM sponsored PCOS consensus workshop group, Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004; 19(1): 41-47.
  8. Loza B., Teunissen J., Otten B. Polycysteus ovariumsyndroom. Tijdschrift voor kindergeneeskunde. 2009; 77(4): 159-64.
  9. Barbieri R.L., Ehrmann D.A., Crowley Jr W.F., Martin K.A. Diagnosis of polycystic ovary syndrome in adults. 2013: [Cited  2014 Apr 21]. Available from: http://www.uptodate.com/.
  10. King J. Polycystic ovary syndrome. J Midwifery Womens Health. 2006; 51(6): 415-22.
  11. Uitgave afdeling patiëntenvoorlichting. Poly Cysteus Ovarium Syndroom. St. Antonius Ziekenhuis: Nieuwegein; 2001.
  12. Teede H., Deeks A., Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010; 8: 41.
  13. Boomsma C.M., Eijkemans M.J., Hughes E.G., Visser G.H., Fauser B.C., Macklon N.S. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006; 12(6): 673-83.
  14. Ehrmann D.A. Polycystic ovary syndrome. New Engl J Med. 2005; 352(12): 1223-36.
  15. Ndefo U.A., Eaton A., Green M.R. Polycystic ovary syndrome: A review of treatment options with a focus on pharmacological approaches. Pharmacy and Therapeutics. 2013; 38(6): 36.
  16. Tang T., Norman R.J., Balen A.H., Lord J.M. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Sys Rev. 2008.
  17. Hajishafiha M., Dehghan M., Kiarang N., Sadegh-Asadi N., Shayegh S.N., Ghasemi-Rad M. Combined letrozole and clomiphene versus letrozole and clomiphene alone in infertile patients with polycystic ovary syndrome. Drug Des Devel Ther. 2013; 7: 1427-31.
  18. Zorginstituut-Nederland. Farmacotherapeutisch Kompas. [cited 2014 Apr 22]. Available from: http://www.farmacotherapeutischkompas.nl/.
  19. Hollinrake E., Abreu A., Maifeld M., Voorhis B.J. van, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril. 2007; 87(6): 1369-76.
  20. Sanchez N. A life course perspective on polycystic ovary syndrome. Int J Womens Health. 2014; 6: 115-22.
  21. Pastore L.M., Patrie J.T., Morris W.L., Dalal P., Bray M.J. Depression symptoms and body dissatisfaction association among polycystic ovary syndrome women. J Psychosom Res. 2011; 71(4): 270-6.
  22. Tasali E., Cauter E. van, Hoffman L., Ehrmann D.A. Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008; 93(10): 3878-84.
  23. World-Health-Organization. International Classification of Diseases (ICD). [cited 2014 Apr 22]. Available from: http://www.who.int/classifications/icd/en/.
  24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition, Text Revision ed. Washington, DC; 2000.
  25. Baune B.T., Stuart M., Gilmour A., et al. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models. Transl Psychiatry. 2012; 2: e92.
  26. Zorginstituut Nederland. Depressie en antidepressiva.  [cited 2014 Apr 22]. Available from: http://farmacotherapeutischkompas.nl/inleidendeteksten/i/inl%20depressie%20en%20antidepressiva.asp#F32.
  27. Zhuang J., Wang X., Xu L., Wu T., Kang D. Antidepressants for polycystic ovary syndrome. Cochrane Database Sys Rev. 2013. 5.
  28. eHealthMe. Review: could Fluoxetine cause Polycystic ovarian syndrome (pcos)? 2013  [cited 2014 22-04]; Available from: http://www.ehealthme.com/ds/fluoxetine/polycystic+ovarian+syndrome+(pcos).
  29. Farrell K., Antoni M.H. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril. 2010; 94(5): 1565-74.
  30. Figlewicz D.P. Endocrine regulation of neurotransmitter transporters. Epilepsy Res. 1999; 37(3): 203-10.
  31. Moran L.J., Ko H., Misso M., et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. J Acad Nutr Diet. 2013; 113(4): 520-45.
  32. Kerchner A., Lester W., Stuart S.P., Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril. 2009; 91(1): 207-12.
  33. Rofey D.L., Szigethy E.M., Noll R.B., Dahl R.E., Lobst E., Arslanian S.A. Cognitive-behavioral therapy for physical and emotional disturbances in adolescents with polycystic ovary syndrome: a pilot study. J Pediatr Psychol. 2009; 34(2): 156-63.
  34. Phillips K.M., Antoni M.H., Carver C.S., et al. Stress management skills and reductions in serum cortisol across the year after Surgery for non-metastatic breast cancer. Cognitive Ther Res. 2011; 35(6): 595-600.
  35. Antoni M.H., Cruess S., Cruess D.G., et al. Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV-infected gay men. Ann Behav Med. 2000; 22(1): 29-37.
  36. Raja-Khan N., Stener-Victorin E., Wu X., Legro R.S. The physiological basis of complementary and alternative medicines for polycystic ovary syndrome. Am J Physiol Endocrinol Metab. 2011; 301(1): E1-E10.
  37. Annagur B.B., Tazegul A., Uguz F., Kerimoglu O.S., Tekinarslan E., Celik C. Biological correlates of major depression and generalized anxiety disorder in women with polycystic ovary syndrome. J of Psychosom Res. 2013; 74(3): 244-7.
  38. Rasgon N.L., Rao R.C., Hwang S., et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disorders. 2003; 74(3): 299-304.
  39. Okamura F., Tashiro A., Utumi A., et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism. 2000; 49(10): 1255-60.
  40. Weiner C.L., Primeau M., Ehrmann D.A. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom med. 2004; 66(3): 356-62.
  41. Rubinow D.R., Hoban M.C., Grover G.N., et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Amer J Obstet Gynec. 1988; 158(1): 5-11.
  42. Bäckström T., Sanders D., Leask R., Davidson D., Warner P., Bancroft J. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom med. 1983; 45(6): 503-07.
  43. Bazarganipour F., Ziaei S., Montazeri A., Foroozanfard F., Kazemnejad A., Faghihzadeh S. Health-related quality of life in patients with polycystic ovary syndrome (PCOS): A model-based study of predictive factors. J Sex Med. 2013; 1-10
  44. Snyder B.S. The lived experience of women diagnosed with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs. 2006; 35(3): 385-92.
  45. Dokras A., Clifton S., Futterweit W., Wild R. Increased risk for abnormal depression scores in women with polycystic ovary syndrome: a systematic review and meta-analysis. Obstet & Gynecol. 2011; 117(1): 145-52.
  46. Elsenbruch S., Hahn S., Kowalsky D., Offner A.H., Schedlowski M., Mann K., Janssen O.E., Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88(12): 5801-7.
  47. Keegan A., Liao L.M., Boyle M. 'Hirsutism': a psychological analysis. J Health Psychol. 2003; 8(3): 327-45.
  48. Yeung E.H., Zhang C., Mumford S.L., et al. Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: the BioCycle Study. J Clin Endocrinol Metab. 2010; 95(12): 5435-42.
  49. Sex hormone-binding globulin. [cited 2014 March 27]. Available from: http://en.wikipedia.org/wiki/Sex_hormone-binding_globulin.
  50. King J., Polycystic ovary syndrome. J Midwifery Womens Health. 2006; 51(6): 415-22.
  51. Luque-Ramirez M., Alvarez-Blasco F., Botella-Carretero J.I., Martinez-Bermejo E., Lasuncion M.A., Escobar-Morreale H.F. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 92(7): 2453-61.
  52. Mitkov M., Pehlivanov B., Terzieva D. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2005; 118(2): 209-13.
  53. Cinar N., Harmanci A., Demir B., Yildiz B.O. Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Hum Reprod. 2012. 27(6): 1840-5.
  54. Sibutramine. [Cited 2014 March 22]. Available from: http://www.drugs.com/cdi/sibutramine.html.
  55. Plancke L. "Quality-of-life" bij obese patiënten met het polycysteus ovarium syndroom (PCOS). 2009; Gent. 1-67.
  56. Li Q., Sullivan N.R., McAllister C.E., Van de Kar L.D., Muma N.A. Estradiol accelerates the effects of fluoxetine on serotonin 1A receptor signaling. Psychoneuroendocrinology. 2013; 38(7): 1145-57.
  57. Stahl S.M. Stahl's Essential Psychopharmacology Neuroscientific Basis and Practical Applications. New York: Cambridge University Press; 2013.
  58. Westlund Tam L., Parry B.L. Does estrogen enhance the antidepressant effects of fluoxetine? J Affect Disord. 2003; 77(1): 87-92.
  59. Rasgon N.L., Dunkin J., Fairbanks L., et al. Estrogen and response to sertraline in postmenopausal women with major depressive disorder: a pilot study. J Psychiatr Res. 2007; 41(3-4): 338-43.

Comments (0)

You don't have permission to comment on this page.

Printable version